Object. The goal of this study was to investigate whether the janus kinase/signal transducer and activator of transcription (JAK/STAT) signal transduction pathway is present and active in meningiomas. The results of these investigations are important for all meningioma therapies that, similar to interferon-␣-2B (IFN␣-2B), depend on activation of this pathway for their effect. The authors were interested in evaluating the importance, if any, of the JAK/STAT pathway in the biology and therapy for these tumors.
URGICAL techniques for meningioma resection are constantly improving, although approximately 15% of patients with meningiomas cannot be cured by surgery alone. In the last few years many different pharmacological therapies have been proposed to treat patients with incompletely resectable meningiomas, histologically aggressive meningiomas, and recurrent meningiomas. One of the most recent protocols is based on chronic systemic administration of recombinant interferon-␣-2B (IFN␣-2B). 16, 34 Although the biological basis for the use of IFN␣-2B is not fully understood, at least some of the in vivo effects on meningiomas seem to be direct and are not mediated by the immune system. Interferon-␣ has a strong growth inhibitory effect on meningioma cell cultures in vitro. 18, 38 Interferon-␣ modulates gene expression via a direct signaling pathway containing the membrane-bound receptors janus tyrosine kinases (JAKs) and signal transducer and activator of transcription (STAT) factors (see Schindler and Darnell for a review 27 ). The JAK/STAT pathway is also known to mediate signaling from activated prolactin, platelet-derived growth factor (PDGF), and interleukin-6 (IL-6) receptors. 27 Prolactin receptors are expressed by more than 50% of the meningiomas tested, 4, 24 and treatment of meningioma cell cultures with prolactin stimulates their growth. 3, 15, 24 The PDGF BB/Sis and PDGF␤ receptors have also been demonstrated to be engaged in an autocrine loop that is important for maintaining meningioma growth in vitro. 17, 23, 29 Interleukin-6 is known to be expressed and secreted by meningioma cells in vivo and in vitro. 1, 2, 21, 31 The role of IL-6 in meningioma biology is still controversial: treatment of meningioma cells in vitro by IL-6 has been shown to result in growth inhibition, 31 whereas in other studies no significant effect was found. 2, 28 These different results may be, at least partially, explained by the difference in activity and content of JAKs and STATs, the downstream effectors of the signal generated by IL-6.
Very little is known about the JAK/STAT pathway in meningiomas, and only very recently the presence of messenger RNAs for Stat1, Stat3, and Stat5 has been demon-strated in meningioma tissue. 28 We recently analyzed the content of JAKs and STATs in neuroepithelial-derived human brain tumors and suggested a possible link between Stat3 expression and the differentiation status of the tumor. 8 In another study we found selective expression of members of these and other families of signaling proteins in the normal brain and reported specific changes in their protein levels during brain maturation. 6, 9, 12 In the present study we analyzed the levels of Jak1, Jak2, Jak3, Tyk2, Stat1, Stat2, Stat3, Stat5, and Stat6 in 17 meningioma specimens collected at the time of first surgery. The results were compared with those obtained by studying the same proteins in normal dura. In addition, we analyzed whether individual STATs present in the tumors are susceptible to being activated.
Materials and Methods

Tissue Samples
Tissue samples were obtained at the time of surgery from 17 patients with meningiomas who were surgically treated at the University of Pavia. Control samples of dura were obtained at autopsy from cadavers without any overt neurological disease; each autopsy was performed within 12 hours after death and dura containing granulations was collected. Clinical characteristics and histological classifications of the tumors are presented in Table 1 .
The dura specimens were obtained from patients who had died of cardiovascular accidents without any sign of preexisting disease of the brain. Samples of dura mater were obtained from a region rich in arachnoidal granulations that are supposed to contain the normal counterpart of meningioma cells (arachnoidal cap cells).
Antibodies Used in the Study
Monoclonal antibody against Tyk2 was used at a concentration of 1:5000. Rabbit polyclonal antibodies against Jak1, Jak2, and Jak3 were used at concentrations of 1:1000, 1:1000, and 1:2000, respectively. Monoclonal antibodies against STAT proteins were applied at the following concentrations: Stat1␣/␤ 1:2500; Stat2 1:250; Stat3 1:2000; Stat5 1:250; and Stat6 1:1000. Polyclonal antibodies against tyrosine-phosphorylated Stat1 and Stat3 were applied at a concentration of 1:1000. Polyclonal antibody against ␤ actin was used at a 1:1000 dilution. Monoclonal antibody against the prolactin receptor was applied at a 1:1000 dilution. The specificity of the antiJak1 and anti-Jak2 antibodies was established by the observation that the major immunoreactive bands recognized by these antibodies corresponded to the published molecular weight of Jak1 and Jak2 and were specifically obliterated by preadsorbing the antibodies with the relative peptide antigen (KTLIEKERFYSRCRPVT-PSC for Jak1 and DSQRKLQFYEDKHQLPAPKC for Jak2). Human-specific Stat4 antibodies are not available.
Western Blot Analysis
Protein extraction and Western blot analysis were performed as described elsewhere. 5, 7, 10, 12 Briefly, each frozen tissue specimen was homogenized using a Teflon-glass homogenizer in lysis buffer (10 l/mg of tissue: 10% glycerol; 50 mM Tris, pH 7.5; 150 mM NaCl; 5 mM ethylenediaminetetraacetic acid; 1 mM ethyleneglycol-bis [␤-aminoethyleter]N,NЈ-tetraacetic acid; 1% Triton X-100; 1 mM Na 3 VO 4 ; 1 mM ZnCl 2 in the presence of 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, and 5 mg/ml leupeptin at 4˚C). The extracts were passed several times through a 1-ml insulin syringe (26 gauge), incubated for 30 minutes at 4˚C, and then cleared by centrifugation. Conditions of protein extraction and solubilization are relatively mild when using this method and most proteins contained in the extracellular matrix remain insoluble and are lost in the pellet after centrifugation. The final extract results in enriched intracellular proteins that, on average, represent the same fraction of total proteins present, as demonstrated by measuring ␤ actin levels in the different samples. Protein content was measured using a protein assay kit. Aliquots of extracts were diluted with sodium dodecylsulfate (SDS) sample buffer and boiled for 5 minutes. Equal amounts of proteins (50 g) were loaded into 7.5% sample buffer for SDS-polyacrylamide gel electrophoresis. After transfer to nitrocellulose, the blots were blocked in 10% nonfat dry milk in Trisbuffered saline and Tween 20 (TBST) (20 mM Tris [pH 7.5]; 500 mM NaCl; and 0.01% Tween 20) overnight at 4˚C. The blots were then incubated for 1 hour at room temperature in primary antibody. After washing with TBST, membranes were exposed to horseradish peroxidase-conjugated secondary antibody for 1 hour at room temperature. Immunoreactivities were detected using the enhanced chemiluminescence method according to the manufacturer's instructions.
Cell Cultures and Immunocytochemical Analysis
Tumor specimens were obtained during surgery and immediately immersed in 4-[2-hydroxyethyl]-1-piperazine-ethanesulfonic acid-buffered Dulbecco's modified Eagle's medium (DMEM). Specimens were mechanically minced and small fragments (maximum diameter Ͻ 50 m) were placed in culture in DMEM supplemented with 10% fetal bovine (FBS) serum. After 1 week, cells outgrowing from the fragments as halos were trypsinized and replated for two additional passages. At the end of the second passage, the cells were plated on glass coverslips and grown to semiconfluence. The medium was then replaced, and IFN␣-2B (1000 U/ml) was added to the cultures. After 12 hours the cultures were washed two times in phosphate-buffered saline (PBS) and fixed in phosphatebuffered paraformaldehyde (2% wt/vol) for 15 minutes at 4˚C. After fixation, the cells were washed several times and then reacted with polyclonal antibodies detecting either the Tyr 701-phosphorylated Stat1 or the Tyr 705-phosphorylated Stat3. Antibodies were revealed using the avidin-biotin complex method with biotinylated alkaline phosphatase. Both X-phosphate and tetrazolium from nitroblue tetrazolium reduction tests were used as substrates for the final enzymatic reaction. At the end of the procedure, the slides were mounted in aqueous medium without counterstaining.
Densitometric Analysis
The relative densities of immunoreactive bands on Western blots were calculated from the area of the peak corresponding to the selected band following acquisition of the blot image through a charge-coupled device video camera module and analysis was performed using a public domain imaging software program. To correct for any differences in cell density, the bands were normalized over the ␤ actin content of the samples, which was used as an internal standard. 
Sources of Supplies and Equipment
The monoclonal antibody against Tyk2 and the monoclonal antibodies against the STAT proteins were obtained from Transduction Laboratories, D.B.A. (Milan, Italy) . The rabbit polyclonal antibodies against Jak1, Jak2, and Jak3 were purchased from Upstate Biotechnology, D.B.A. (Milan, Italy) . Polyclonal antibody against Tyr 701-phosphorylated Stat1 and polyclonal antibody against Tyr 705-phosphorylated Stat3 were obtained from New England Biolabs, CELBIO (Milan, Italy) and the polyclonal antibody against ␤ actin from Sigma (Milan, Italy). The monclonal antibody against the prolactin receptor was purchased from Affinity Bioreagents, Inc. (Milan, Italy) . Amersham (Milan, Italy) manufactured the enhanced chemiluminescence kit.
The FBS was obtained from GIBCO, Life Technologies (Milan, Italy) and the IFN␣-2B from Intron A-Schering-Plough (Milan, Italy). Antibodies were revealed using the Vectastain Elite ABC kit available from Vector Laboratories (Burlingame, CA). The X-phosphate and tetrazolium were acquired from Boehringer Mannheim (Milan, Italy).
The charge-coupled device video camera module was obtained from Nikon (Tokyo, Japan) and the Image 1.52 computer software program was from Wayne Rasband, National Institutes of Health Research Services Branch (Bethesda, MD).
Results
Expression of JAKs and STATs in Meningiomas
In all meningiomas studied, levels of Jak3 and Tyk2 were below the limits of our detection methods. On the contrary, immunoreactive bands at the appropriate molecular weights were found for Jak1 and Jak2 in all meningiomas tested (Fig. 1) . As shown in Fig. 1 , the intensities of the respective bands were always significatively higher than those found in normal dura (Figs. 2 and 3 ). This remained true even after correction for the increased cellularity found in tumors compared with dura, as described in Materials and Methods.
Immunoreactive bands for the various STATs were also detected at the expected molecular weights (Stat1 91 and 84 kD; Stat2 113 kD; Stat3 92 kD; Stat5 90 and 80 kD; and Stat6 100 kD). In all cases the immunoreactivities were always higher in meningioma tissues than in control dura specimens (Fig. 1) . Among the control specimens, Stat3 was the most frequently represented STAT in the dura (Figs. 1 and 2) . The average levels of the various STATs were all comparable in meningiomas (Fig. 2 ). Significant differences in relative levels, however, were found when meningiomas were subdivided according to current neuropathological criteria (Fig. 3) . The highest levels of STATs were consistently found in transitional meningiomas, with the exception of Stat2 for which the average levels did not vary among the different histological types (Fig. 3) . A statistically significant difference (p = 0.05) was reached only for Stat6 when comparing transitional meningiomas with fibroblastic and meningothelial meningiomas considered together (Fig. 3) .
Phosphorylated STATs Found in Meningioma Cells in Vivo
Nonactivated STAT transcription factors are normally found in the cytoplasm. After tyrosine phosphorylation, STAT proteins translocate into the nucleus and bind to DNA elements, leading to transcriptional activation of target genes. Tyrosine phosphorylation and nuclear translocation are, therefore, indicative of STAT activation. Meningioma cells were exposed to IFN␣-2B in vitro and immunocytochemical analysis using anti-tyrosine-phosphorylated Stat1 and Stat3 antibodies was performed. As shown in Fig. 4 , Stat 1 and Stat3 were found to vary their phosphorylation and their cellular localization in response to IFN␣ stimulation. Phosphorylation and nuclear translocation of STATs are indicative of STAT activation. We determined the levels of Stat1 and Stat3 phosphorylation by using Western blot analysis performed with antibodies that only recognize the specific tyrosine-phosphorylated STATs. The levels of phosphorylated Stat1 and Stat3 were compared with the total (unphosphorylated and phosphorylated) content of the same proteins. This analysis revealed that Stat3 was activated in all samples in which the transcription factor was expressed (Fig. 4) , and the amount of phosphorylated STAT was proportional to the total protein present. The same finding was observed for Stat1 (data not shown).
Interferon-␣-2B-Induced STAT Phosphorylation in Meningioma Cell Cultures
In meningiomas the integrity of the signal transduction pathway that leads from activation of a membrane receptor to STAT phosphorylation was tested in vitro. Short- Stat3 phosphorylation was demonstrated by immunocytochemical analysis performed using antibodies against specific tyrosine-phosphorylated STATs. In untreated cultures most cells showed very low immunoreactivity for the phosphorylated isoform of Stat1 and Stat3 ( Fig. 5A and  C) . After a 12-hour treatment with IFN␣-2B, the signal greatly increased, especially in the nucleus (Fig. 5B and  D) , as expected for cytoplasmic proteins that translocate to the nucleus once they are activated by phosphorylation.
Discussion
Our results show that members of the JAK and STAT superfamilies are widely expressed in meningiomas and their values are, on average, higher than those found in normal meninges. Furthermore, we found that Jak3 and Tyk2 proteins, whose expression is restricted to a limited number of extracerebral tissues (lymphocytes and other blood cells), are not expressed in meningiomas. The lack of detectable Jak3 and Tyk2 suggests that our data reflect the levels of JAKs and STATs inside the meningiomas and that these levels are not significantly altered by the presence of infiltrating lymphocytes or other blood-derived cells. All other proteins studied were present above the detection level of our technique. The average level of expression of JAKs and STATs was always higher in meningioma tissue than in control specimens, even after correction for a possible difference in cell density that may alter the ratio of intracellular/extracellular-derived proteins (that is, the bands in Western blotting were normalized over the ␤ actin content of the samples). Because we only considered typical meningiomas in which mitotic activity is very low, an imbalance in the ratio of proliferative cells/quiescent cells should not influence the results.
We found that STATs are phosphorylated in vivo in the meningioma and the dura. Tyrosine phosphorylation of Stat1 and Stat3 indicates that the JAK/STAT pathway is active in meningiomas in vivo. Several signaling molecules and pathways dependent on JAK/STAT activation for their effects are known to be involved in modulation of meningioma growth. The PDGF BB/Sis and PDGF␤ receptors have been demonstrated to be engaged in an autocrine loop that is important for maintaining meningioma growth in vitro. 17, 23, 29 Recently, it was demonstrated that PDGF BB stimulation and, to a lesser extent, PDGF AA stimulation rapidly induce Stat6 DNA binding activity in NIH 3T3 fibroblasts. 25 Analysis of Stat6 expression and levels has not yet been reported in meningioma cases. In our analysis, we found strong Stat6 expression in these tumors, with higher values found in transitional meningiomas. This suggests that the PDGF/Stat6 pathway could be an important course to meningiomas' growth. Prolactin, whose receptor also activates the JAK/STAT pathway, enhances meningioma growth in vitro 3, 15, 24 and, presumably, in vivo. Prolactin receptor activation by prolactin induces tyrosine phosphorylation of Jak2, which, in turn, activates Stat1, Stat3, and Stat5. 11, 33 We infer from our data that, on average, Jak2 levels in meningiomas are 10 times higher than those in controls. The Stat1, Stat3, and Stat5 proteins in the meningioma specimens analyzed were present at values higher than in controls. However, in one meningotheliomatous meningioma, the relative levels of these proteins were extremely low or absent. The lack of appropriate STATs together or, alternatively, the variable expression of the prolactin receptor 4, 24 may also contribute to the variability in the reported effects of prolactin on meningioma growth. Variable levels of prolactin receptors were also found in our specimens (data not shown). The effects of IL-6, which is expressed and secreted by meningioma cells, 1,2,21,31 also depend on the activation of the JAK/STAT pathway.
In our short-term meningioma cultures in vitro, the JAK and STAT proteins were not strongly activated, as demonstrated by immunocytochemical staining with antibodies specific for the phosphorylated isoform of the proteins. However, the integrity of the pathway was demonstrated by the effect of its activation on IFN␣-2B treatment.
Interferon-␣ effects are initiated by binding of IFN to the two IFN␣ receptors, IFN␣-R1 and IFN␣-R2. Activated IFN␣ receptors associate with the two cytoplasmic kinases Tyk2 and Jak1, 36 which, in turn, tyrosine-phosphorylate Stat1, Stat2, and Stat3. 14, 26, 37 Activated STATs dimerize to form homo-or heterologous complexes that translocate to the nucleus where they modulate transcription by binding to specific DNA elements. 14, 22 Our observation of STATs presence in the meningioma tumors anticipates a finding of a possible involvement of these transcription factors in responses of tumor cells to cytokines or growth factors. The administration of recombinant IFN␣-2B is one of the most interesting pharmacological therapies proposed for the cure of meningiomas. The antiproliferative effect of IFN␣ in hematopoietic cells is mediated by activated Stat1, Stat2, and Stat3. 20 The current interest in IFN␣ as a possible therapeutic agent in meningiomas led us to investigate whether Stat1 and Stat3 are activated in these tumors. With the exception of Tyk2, in the meningioma specimens tested in our study, we found the presence of all proteins known to be involved in IFN␣ signal transduction. In any case, it has been demonstrated that Tyk2 is not essential for IFN␣ signaling 13 and Jak1 functions upstream of Tyk2. 19 An activated IFN␣ receptor may also stimulate serine kinases in the phosphatidylinositol pathway. 32 This pathway is also dependent on the presence of STATs. Particularly, Stat3 acts as an adapter protein to couple the IFN receptor to the p85 regulatory subunit of phosphatidylinositol kinase. 26 Our study shows that Stat3 is expressed in meningiomas and reaches its higher values in the transitional histological type. These data are in agreement with recent work demonstrating the presence of messenger RNAs for Stat1 and Stat3 28 in meningioma. Interestingly, we found very low levels of Stat1, Stat2, and Stat3 in one fibroblastic meningioma and one meningotheliomatous meningioma. Alteration in STAT content may certainly contribute to the variable response to IFN␣ obtained in human trials.
Defects in the STAT signaling pathway may profoundly alter the sensitivity of cells to the growth inhibitory effects of IFN␣. Resistance to INF␣ due to lack of Stat1 expression has already been documented in cell lines derived from hematological malignancies 30 and melanoma cells, 35 tumors that are usually sensitive to IFN␣. In our study we found that Stat1 and Stat3 are activated in meningioma cell cultures following IFN␣ treatment, which is suggestive of a direct effect of IFN␣ on these cells. Moreover, we observed that Stat1 and Stat3 are normally activated in meningioma specimens, suggesting that different stimuli (growth factors or cytokines) may exist in the tumoral and peritumoral tissues and are capable of activating these two STATs.
Finally, a comparison between JAK and STAT protein expression in human neuroepithelial tumors 8 and levels of the same proteins in meningiomas, as demonstrated in this study, highlights the existence of wide differences, indicating that different mechanisms control growth and differentiation in these two classes of brain tumors.
